Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo:activation of hepatic c-Jun N-terminal kinases 1 and 2, and mitogen-activated protein kinase kinases 4 and 7 by Finch, A et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of mitogen-activated protein kinase pathways used by
interleukin 1 in tissues in vivo
Citation for published version:
Finch, A, Davis, W, Carter, WG & Saklatvala, J 2001, 'Analysis of mitogen-activated protein kinase
pathways used by interleukin 1 in tissues in vivo: activation of hepatic c-Jun N-terminal kinases 1 and 2, and
mitogen-activated protein kinase kinases 4 and 7' Biochemical Journal, vol 353, no. Pt 2, pp. 275-81.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Biochemical Journal
Publisher Rights Statement:
copyright 2001 Biochemical Society
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Biochem. J. (2001) 353, 275–281 (Printed in Great Britain) 275
Analysis of mitogen-activated protein kinase pathways used by interleukin 1
in tissues in vivo : activation of hepatic c-Jun N-terminal kinases 1 and 2,
and mitogen-activated protein kinase kinases 4 and 7
Andrew FINCH1,2, W. DAVIS1, Wayne G. CARTER3 and Jeremy SAKLATVALA4
Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH, U.K.
The effects of interleukin 1 (IL-1) are mediated by the activation
of protein kinase signalling pathways, which have been well
characterized in cultured cells. We have investigated the ac-
tivation of these pathways in rabbit liver and other tissues after
the systemic administration of IL-1a. In liver there was 30–40-
fold activation of c-Jun N-terminal kinase (JNK) and 5-fold
activation of both JNK kinases, mitogen-activated protein kinase
(MAPK) kinase (MKK)4 and MKK7. IL-1a also caused 2–3-
fold activation of p38 MAPK and degradation of the inhibitor of
nuclear factor jB (‘IjB’), although no activation of extracellular
signal-regulated protein kinase (ERK) (p42}44 MAPK) was
observed. The use of antibodies against specific JNK isoforms
showed that, in liver, short (p46) JNK1 and long (p54) JNK2 are
the predominant forms activated, with smaller amounts of long
JNK1 and short JNK2. No active JNK3 was detected. A similar
INTRODUCTION
Interleukin 1 (IL-1) is a potent pro-inflammatory cytokine
produced by activated monocytes and macrophages that causes
pleiotropic effects in many different cell types. It is made at sites
of injury or infection and, by up-regulating adhesion molecules
and chemotaxins, causes leucocytes to move from blood vessels
into tissues. Local production of IL-1 also causes the resorption
of connective tissue matrices by resident cells. In addition, IL-1
exerts systemic effects ; most notably it causes fever and the
production of acute-phase proteins by the liver. Excessive pro-
duction of IL-1 and the biologically similar cytokine tumour
necrosis factor (TNF) is strongly implicated in causing tissue
damage in chronic inflammatory diseases such as rheumatoid
arthritis.
The signalling pathways activated by IL-1 have been widely
studied and elucidated in cultured cells. However, little has been
reported of the pathways activated by the cytokine in tissues in
io. IL-1 signals by binding to the type 1 IL-1 receptor (IL-1R1).
On ligand binding, IL-1R1 recruits its co-receptor, the IL-1-
receptor accessory protein (‘IRAcP’) [1] and a complex is formed
that includes the IL-1-receptor-activated kinase (‘ IRAK’) [2],
and the death-domain-containing protein Myd88 [3]. This com-
plex, via an association with TNF-receptor-associated factor 6
(‘TRAF 6’) [4], activates downstream pathways. In fibroblasts,
Abbreviations used: CMV, cytomegalovirus ; DMEM, Dulbecco’s modified Eagle’s medium; E-64, trans-epoxysuccinyl-L-leucylamido-
(4-guanidino)butane; ERK, extracellular signal-regulated protein kinase ; GST, glutathione S-transferase ; HA, haemagglutinin ; IjB, inhibitor of nuclear
factor jB; IL-1, interleukin 1 ; JNK, c-Jun N-terminal kinase ; MAPK, mitogen-activated-protein kinase ; MAPKAPK-2, MAPK-activated protein kinase 2;
MKK, MAPK kinase ; NF-jB, nuclear factor jB; TIPK, TNF- and IL-1-activated protein kinase ; TNF, tumour necrosis factor.
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3 Present address : Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, U.S.A.
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pattern of JNK activation was seen in lung, spleen, skeletal
muscle and kidney. Significant JNK3 activity was detectable only
in the brain, although little activation of the JNK pathway in
response to IL-1a was observed in this tissue. This distribution of
active JNK isoforms probably results from a different expression
of JNKs within the tissues, rather than from a selective acti-
vation of isoforms. We conclude that IL-1a might activate a
more restricted set of signalling pathways in tissues in io than
it does in cultured cells, where ERK and JNK3 activation are
often observed. Cultured cells might represent a ‘repair ’ pheno-
type that undergoes a broader set of responses to the cytokine.
Key words: liver, nuclear factor jB, stress-activated protein
kinase.
for example, IL-1 activates five downstream protein kinase
pathways. These include the three mitogen-activated-protein
kinase (MAPK) pathways, which are the extracellular signal-
regulated kinase (ERK) or p42}p44 MAPK pathway [5], the p38
MAPK pathway [6] and the c-Jun N-terminal kinase (JNK)
pathway [7]. IL-1 also activates the inhibitor of nuclear factor jB
(IjB) kinase pathway [8,9], which leads to the activation of
nuclear factor jB (NF-jB). Lastly, the TNF- and IL-1-activated
protein kinase (TIPK) is also activated by IL-1 in some cells ; this
enzyme, which phosphorylates a QSL (Gln-Ser-Leu) motif in b
casein in itro [10], is less well characterized and has not
been cloned. These pathways regulate the expression of target
genes by controlling transcription factor activity and also post-
transcriptional events such as mRNA stability.
The MAPKs are a family of proline-directed serine}threonine
protein kinases that are activated in response to many extra-
cellular stimuli. This results from their phosphorylation on
threonine and tyrosine residues in a Thr-Xaa-Tyr motif, in which
the intervening amino acid varies between family members.
Phosphorylation of both hydroxyamino acids is catalysed by a
family of dual-specificity kinases [MAPK kinases (MKKs)] and
is required for maximal MAPK activity.
The ERK pathway is strongly activated by growth factors
such as platelet-derived growth factor (‘PDGF’), as well as many
other stimuli. In contrast, p38 MAPK and JNK are at best
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weakly activated by growth factors but are strongly activated by
cellular stresses and by pro-inflammatory agents such as en-
dotoxin and the cytokines IL-1 and TNF [6,11–14]. Each type of
MAPK is specifically regulated by MKKs: ERK by MKK1 and
MKK2, p38 by MKK3 and MKK6, and JNK by MKK4
and MKK7. The nature of the kinases upstream of MKKs in
IL-1 signalling is not entirely clear. Many MKK kinases have
been cloned that can cause the activation of p38MAPKand JNK:
the TGFb-activated kinase (TAK1), which is activated by IL-1
and (indirectly) activates p38 and JNK, is the best candidate for
an IL-1-activated MKK kinase [15].
We previously purified two forms of activated JNK2 from
liver of rabbits injected with IL-1 [7] and subsequently showed
that an IL-1-stimulated activator of JNK purified from the tissue
corresponded to MKK7 [16]. There are three closely related JNK
genes (1, 2 and 3) that give rise to different splice variants
resulting in ten potential isoforms [17]. The physiological reason
for the existence of so many isoforms is not known and the
nature of the JNK proteins expressed by different tissues has not
been explored. We have made antisera against specific JNK
forms and used them to investigate the nature of the IL-1-
activated JNKs in liver and other tissues. We have also further
investigated the MKKs involved in JNK activation and also the
effect of IL-1a in io on the other signalling pathways potentially
used by the cytokine. Our results suggest that the signalling
pathways activated by IL-1a in tissues in io might be more
restricted than those commonly seen in cultured cells.
MATERIALS AND METHODS
Materials
All reagents were from Sigma (Poole, Dorset, U.K.) or Merck
Ltd (Poole, Dorset, U.K.) unless stated otherwise. Human IL-1a
was made as described [12]. [c-$#P]ATP (Redivue) was from
Amersham International (Little Chalfont, Bucks., U.K.). Protein
G–Sepharose was from Amersham Pharmacia Biotech. cDNA
for histidine-tagged murine MAPK-activated protein kinase 2
(MAPKAPK-2) was a gift from M. Gaestel (Max Delbru$ ck
Center for Molecular Medicine, Berlin, Germany). cDNA for
JNK2a2 (K55R) and JNK1a2 were gifts from M. Kracht
(Hannover Medical School, Hannover, Germany). cDNA species
for rat GST–SAPKb (rat homologue of JNK3a2) and human
glutathione S-transferase-conjugated Jun (GST–Jun) (residues
1–135) were gifts from J. R. Woodgett (Ontario Cancer Institute,
Toronto, Ontario, Canada). Recombinant proteins were
expressed in Escherichia coli and the proteins were purified by
standard methods. Rat anti-haemagglutinin (anti-HA) antibody
was from Boehringer Mannheim (Mannheim, Germany). Murine
anti-JNK1 monoclonal antibody (raised against the short form
of JNK1) was from PharMingen (San Diego, CA, U.S.A.).
Rabbit antibodies against ERK-2, MKK4 and IjB were from
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Rabbit
antisera against synthetic peptides were all raised at the
Babraham Institute (Cambridge, U.K.). Their specificities were
as follows: anti-(short JNK 2) was against the peptide
KNGVVKDQPSAQMQQ (single-letter amino acid codes) (hu-
man, C-terminal 15 residues), anti-(long JNK 2) was against
DSSLDASTGPLEGCR (human, C-terminal 15 residues), anti-
(short JNK 3) was against GVVKGQPSPSAQVQQ (human,
C-terminal 15 residues), anti-(p38 MAPK) was against
ISFVPPPLDQEEMES (rat p38a, C-terminal 15 residues) and
anti-MKK7 was against CRTSGVLSQHHLPFFR (murine,
C-terminal 15 residues).
Plasmids
The HA-tag expression vector pCMV3RHA (in which CMV
stands for cytomegalovirus) was constructed by the insertion
of an oligonucleotide (5«-CTAGCATGTACCCATACGATG-
TTCCTGACTATGCGGAATTCTCGAGATATCTAGA-3«) at
the XbaI site of pCMV3R [18]. The 5« XbaI site was destroyed
and the remaining XhoI and XbaI sites (shown in bold) were
used for insertion of JNK cDNA species. JNKs were amplified
by PCR with the following primers (restriction sites are in bold;
initiating methionine residues were altered) : 5« for JNK1a1
(short JNK1), 5«-GCGCCTCGAGGAGCAGAAGCAAGCG-
TGACAACAAT-3« ; 3« for JNK1a1, 5«-GCGCCTCGAGTC-
ACTGCTGCACCTGTGCTAAAGGAGAGGGCTGCCC-
C-3« ; 5« for JNK1a2 (long JNK1), 5«-GCGCACTAGTGAG-
CAGAAGCAAGCGTGACAACAAT-3« ; 3« for JNK1a2, 5«-
GCGCACTAGTTCATCTACAGCAGCCCAGAGG-3« ; 5« for
JNK2a1 (short JNK2), 5«-GCGCCTCGAGGAGCGACAGT-
AAATGTGACAGTC-3« ; 3« for JNK2a1, 5«-GCGCCTCGAG
TTACTGCTGCATCTGTGCTGAAGGCTGATCTTTTAC-
AAC-3« ; 5« for JNK2a2 (long JNK2), 5«-GCGCACTAGTGA-
GCGACAGTAAATGTGACAGTC-3« ; 3« for JNK2a2, 5«-G
CGCACTAGTCTATCATCGACAGCCTTCAAGGGG-3« ; 5«
for JNK3a1 and JNK3a2 (short JNK3 and long JNK3), 5«-
GCGCCTCGAGGAGCCTCCATTTCTTATACTACTGCA-
G-3« ; 3« for JNK3a1, 5«-GCGCCTCGAGTCACTGCTGCAC-
CTGTGCTGAAGGAGAAGGCTGTC-3« ; 3« for JNK3a2, 5«-
GCGCCTCGAGTCACCTGCAACAACCCAGGG-3«.
Expression of recombinant JNKs in Cos-7 cells
Each cDNA (10 lg) was mixed with 50 ll of Superfect trans-
fection reagent (Quiagen, Crawley, West Sussex, U.K.) and
500 ll of Dulbecco’s modified Eagle’s medium (DMEM). After
15 min, 3 ml of DMEM}10% (v}v) fetal calf serum was added
and this mixture was added to a 10 cm dish of Cos-7 cells
(approx. 75% confluence). After 3 h, a further 10 ml of DMEM}
10% (v}v) fetal calf serum was added to each dish and the cells
were left for 40 h. The medium was then removed and cells were
lysed in 2 ml of lysis buffer [20 mM Hepes (pH 7.4)}20 mM
b-glycerophosphate}10 mM NaF}0.5 mM EDTA}0.5 mM
EGTA}0.2 M NaCl}2 mM dithiothreitol}1 mM PMSF}
10 lg}ml aprotinin}10 lM trans-epoxysuccinyl-l-leucylamido-
(4-guanidino)butane (E-64)}1% (v}v) Triton X-100) for 10 min
on ice. Lysates were clarified by centrifugation in a Microfuge
(16000 g for 15 min at 4 °C).
Immunoprecipitation of recombinant JNKs
Expression of recombinant HA-JNKs was assessed by Western
blotting on PVDF membrane with anti-HA antibody at 1:2000
dilution. All blocking and antibody incubations were in Tris-
buffered saline}0.1% (v}v) Tween 20}5% (v}v) non-fat milk.
Blots were developed by enhanced chemifluorescence (Amersham
International) and antigen was quantified with a FLA-2000
PhosphorImager (Fuji, Raytek Scientific Ltd, Sheffield, South
Yorks., U.K.). Lysates were then adjusted by adding lysate of
untransfected Cos-7 cells to give approximately the same levels
of HA-JNKs and total protein. Adjusted lysates were split into
five for the preparation of immunoprecipitates, which were made
with non-immune serum, the anti-JNK1 monoclonal antibody or
the rabbit antisera against short JNK2, long JNK2 and short
JNK3. The adjusted lysates were mixed with an equal volume of
2‹immunoprecipitation buffer [1‹immunoprecipitation buffer
consists of 20 mM Hepes, pH 7.4, 20 mM b-glycerophosphate,
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10 mM NaF, 0.5 mM EDTA, 0.5 mM EGTA, 0.2 M NaCl,
2 mM dithiothreitol, 1% (v}v) Nonidet P40, 0.5% sodium
deoxycholate and 0.1% SDS], 30 ll of Protein A–agarose and
5 ll of a non-immune serum or relevant antiserum or antibody.
Samples were rotated for 3 h at 4 °C. Protein A–agarose pellets
were then washed three times in 1 ml of immunoprecipitation
buffer and twice in 1 ml of kinase wash buffer [20 mM Hepes
(pH 7.4)}20 mM b-glycerophosphate}10 mM NaF}0.5 mM
EDTA}0.5 mM EGTA}2 mM dithiothreitol}10 mM MgCl
#
].
SDS}PAGE loading buffer (50 ll) was added to the Protein
A–agarose beads and samples were subjected to SDS}PAGE.
The immunoprecipitation of HA-JNKs was assessed by Western
blotting with the anti-HA antibody as described above.
Injection of animals with IL-1a
Female Dutch rabbits were sedated with Hypnorm [Janssen
Pharmaceuticals (Wantage, Oxon., U.K.)] and injected via an ear
vein with IL-1a (5 lg}kg) or vehicle. After 4 min a rapidly lethal
anaesthetic [Sagatal (pentobarbitone sodium urethane) from
Rhone Merieux (Harlow, Essex, U.K.)] was administered and
the tissues were rapidly removed and placed on ice before
processing or storage at fi70 °C. The estimated times from the
injection of IL-1 to placing tissues on ice were as follows: liver,
6 min; spleen, 7 min; lung, 8 min; skeletal muscle, 9 min; brain,
11 min; kidney, 12 min.
Preparation of tissue extracts
For immunoprecipitation or Western blotting, 250 mg of tissue
(fresh or frozen) was homogenized in a Polytron (Kinematica,
Littan, Switzerland) in 5 ml of lysis buffer lacking Triton X-100.
For MonoQ chromatography, homogenates were prepared in
chromatography buffer : this was the lysis buffer but lacking both
Triton X-100 and NaCl and in which 20 mM Tris}HCl, pH 8.5,
was substituted for Hepes. Homogenates were clarified by
centrifugation in a Microfuge (16000 g for 15 min at 4 °C).
Western blotting for IjB
Western blots were performed essentially as described for anti-
HA blots ; anti-IjB was used at 1:1000 dilution, the blots were
developed with enhanced chemiluminescence rather than en-
hanced chemifluorescence and proteins were detected on X-ray
film.
MonoQ chromatography
A MonoQ column [1 ml (HR 5}5) ; Pharmacia Biotech, Uppsala,
Sweden] was equilibrated in chromatography buffer ; 20 mg of
liver sample was applied to the column. A 20 ml gradient from
0 to 0.5 M NaCl in chromatography buffer was used to elute
proteins ; 20 fractions (1 ml) were collected and JNK activity in
the fractions was measured directly in the kinase assay or after
immunoprecipitation with JNK antibodies. An alternative pro-
tocol was used to generate fractions for in-gel kinase assays.
Here, homogenate from IL-1-treated rabbit liver (generated as
above) containing 1 mg of total protein was applied to a pre-
equilibrated MonoQ PC 1.6}5 column; proteins were eluted as
20 fractions (0.2 ml) with a linear 0–0.3 M NaCl gradient.
Immunoprecipitation of chromatography fractions and tissue
extracts
The protein concentration of tissue extracts was adjusted to
2 mg}ml (as judged by Bradford protein assay). Tissue extract
(500 ll) or chromatography fraction aliquot (300 ll) was mixed
with an equal volume of 2‹immunoprecipitation buffer (for the
assay of MKK4 and MKK7, sodium deoxycholate was omitted
from the immunoprecipitation buffer at this stage and in sub-
sequent washes) containing 5 ll of diluted antibody or antiserum,
and 30 ll of Protein A–agarose slurry. Samples were then treated
as described for the immunoprecipitation of recombinant JNKs;
the kinases immunosorbed to Protein A–agarose were assayed
for activity. Immunoprecipitations for analysis by in-gel kinase
assay were prepared with 180 ll of chromatography fraction,
180 ll of 2‹immunoprecipitation buffer, 5 ll of anti-JNK1
antibody and 30 ll of Protein G–Sepharose slurry. Immuno-
precipitations of JNKs from cultured cells (MRC-5 or HeLa)
were performed similarly, after treatment of cells with 20 ng}ml
IL-1a (or vehicle) for 15 min.
Protein kinase assays
Samples of chromatography fractions, or protein A beads
containing immunosorbed protein kinase, were assayed for
protein kinase activity as follows. To each pellet was added 10 ll
of kinase wash buffer, 10 ll of stock solution of substrate at
100 lg}ml [His-MAPKAPK-2 for p38MAPK;GST–Jun (1–135)
for JNK; myelin basic protein for p42 MAPK; GST–JNK2a2
(K55R) for MKK4 and MKK7] and 10 ll of kinase assay buffer
[150 mM Tris}HCl (pH 7.4)}30 mM MgCl
#
}60 lM ATP}
0.4 lCi}ll [c-$#P]ATP}1 mM PMSF}10 lg}ml aprotinin}10 lM
E-64]. Samples were shaken for 20 min at room temperature and,
after the addition of 20 ll of SDS sample buffer, were run on
SDS}PAGE. Gels were stained and dried and the incorporation
of $#P into the substrate was quantified with a PhosphorImager.
In-gel kinase assays
Samples (10 ll of monoQ chromatography fractions or entire
pellets from immunoprecipitations) were boiled in sample buffer
and separated on SDS}10% polyacrylamide mini-gels containing
1.2 mg}ml GST–Jun (1–135). Gels were rinsed three times at
room temperature in 20% (v}v) propan-2-ol}50 mM Tris}HCl
(pH 8.0) (20 min for each rinse) to remove SDS, and three times
(20 min each) in 50 mM Tris}HCl (pH 8.0)}5 mM 2-mercapto-
ethanol. Proteins were denatured at room temperature with two
washes (30 min each) in 7 M guanidinium chloride}50 mM
Tris}HCl (pH 8.0)}5 mM 2-mercaptoethanol and renatured at
4 °C with five washes (one for 30 min, two for 1 h, one for 14 h
and one for 30 min) in 50 mM Tris}HCl (pH 8.0)}5 mM
2-mercaptoethanol}0.04% (v}v) Tween 40. Gels were re-equili-
brated to room temperature with two 30 min washes in 40 mM
Hepes (pH 8.0)}2 mM dithiothreitol}10 mM MgCl
#
. Phos-
phorylation of in-gel substrate was then performed for 3 h
at room temperature in 40 mM Hepes (pH 8.0)}2 mM dithio-
threitol}0.5 mM EGTA}10 mM MgCl
#
}50 lM ATP containing
0.6 mCi}ml [c-$#P]ATP. Gels were then washed extensively with
5% (w}v) trichloroacetic acid}1% (w}v) disodium pyro-
phosphate until no further radioactivity was being stripped from
the gels. Incorporation of labelled phosphate was quantified by
PhosphorImager.
RESULTS
Characterization of anti-JNK antibodies
The terminology of the JNK isoforms is as follows [17] : JNK1,
JNK2 and JNK3 represent three highly similar genes. JNK1 and
JNK2 occur as a or b variants depending on the presence of
short alternative sequences in subdomains IX and X. The antisera
used here did not distinguish between these. All three JNKs
occur in alternatively spliced forms, giving rise to distinct
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Figure 1 Specificity of anti-JNK antibodies
(A) Cos-7 cells were left untransfected (0) or were transfected with HA-tagged JNKs. Cell lysates
were adjusted to give similar HA-JNK and protein concentrations. Western blotting of the lysates
with anti-HA antibody is shown in the bottom panel (lysates). Immunoprecipitates were prepared
from the adjusted lysates by use of the following : the anti-JNK1 antibody and the anti-(short
JNK2), anti-(long JNK2) and anti-(short JNK3) antisera. Precipitated HA-JNKs were detected
by Western blotting with the anti-HA antibody and enhanced chemiluminescence. See the
Materials and methods section for details. Some cross-reactivity of the (anti-rat) secondary
antibody with (murine) heavy chain is observed in the top panel. (B) Immunoprecipitates from
lysates (corrected for protein concentration) of cells stimulated with IL-1 or vehicle were
prepared with the antibodies against JNK1, long JNK2, short JNK3 or non-immune rabbit serum
(NI) as indicated, and assayed for activity against GST–Jun (1–135). The result shown is typical
of three experiments.
C-termini. Thus each JNK has a short or a long form: the short
forms designated JNK1a1, JNK1b1, JNK2a1 and JNK2b1 are
detected as 46 kDa proteins ; JNK3a1 is 48 kDa. The long forms
JNK1a2, JNK1b2, JNK2a2 and JNK2b2 correspond to 54 kDa
proteins and JNK3a2 is 57kDa [17]. We made rabbit antisera
against the C-terminal 15 residues of the long and short forms of
JNK2 and the short form of JNK3. We refer to these as anti-
(short JNK2), anti-(long JNK2) and anti-(short JNK3). A
monoclonal antibody raised against the short form of JNK1 was
obtained commercially.
The specificity of the rabbit antisera for immunoprecipitation
of different JNK isoforms was determined as follows. cDNA
species were used as templates for the PCR-based generation of
short and long a forms of each JNK. These six constructs were
cloned into a mammalian expression vector (pCMVRHA) and
expressed with an N-terminal HA tag in COS-7 cells. Lysates
were prepared and the levels of expression of recombinant JNKs
Figure 2 IL-1 activates JNK1 and JNK2 in rabbit liver
(A) MonoQ chromatography was performed on extracts of liver from rabbits injected with vehicle
(control) or IL-1. JNK activity of the fractions was detected by assaying them on GST–Jun
(1–135) substrate (top two panels). Immunoprecipitates were prepared from equal volumes of
the fractions by using the four anti-JNK antibodies ; precipitated JNK activity was detected
in the kinase assay as described above (bottom four panels). See the Materials and methods
section for details. (B) MonoQ chromatography fractions (see the Materials and methods section
for details of the shallower NaCl gradient used) were assayed for activity of long (p54) JNK and
short (p46) JNK activated by IL-1 in rabbit liver by in-gel kinase assay against GST–Jun
(1–135). (C) Immunoprecipitation of early JNK (p54 and p46) peaks by anti-JNK1 antibody,
shown on in-gel assay.
(HA-JNKs) were examined by Western blotting with an anti-HA
antibody. Development of the blot by enhanced chemi-
fluorescence allowed the quantification of HA-JNK expression
with the use of a PhosphorImager. Lysates were then adjusted by
dilution with lysates of untransfected Cos-7 cells to approxi-
mately equal HA-JNK concentrations (Figure 1A, bottom
panel). Immunoprecipitates were prepared from these adjusted
lysates by the addition of the four anti-JNK antisera ; levels of
precipitated HA-JNKs were assessed by Western blotting with
the anti-HA antibody (Figure 1A, top four panels). The antibody
against JNK1 precipitated both short and long forms but did not
react with JNK2 or JNK3. The antisera against short JNK2,
against long JNK2 and against short JNK3 all specifically
immunoprecipitated their respective antigens.
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Figure 3 Activation of JNKs by IL-1 in rabbit tissues
(A) Rabbit tissues were analysed in pairs, one unstimulated and one IL-1-stimulated.
Immunoprecipitates were prepared from tissue lysates with the anti-JNK1, the anti-(long JNK2)
and the anti-(short JNK3) antibodies. A non-immune serum (NI) was included as a control. The
activity of the precipitated JNKs was measured on GST–Jun (1–135) substrate. Phosphorylated
substrate was detected by autoradiography. (B) Activation of long JNK2 by IL-1 in rabbit tissues,
measured as described above. A PhosphorImager was used to quantify substrate
phosphorylation. The fold activation of long JNK2 in each tissue on stimulation by IL-1 was
determined in three pairs of rabbits. Results are geometric means‡S.E.M. for these triplicates.
The ability of the antibodies against JNK1, long JNK2 and
short JNK3 to precipitate active kinase from cultured cells was
assessed by kinase assay in itro with GST–Jun (1–135) as
substrate. Treatment of both MRC-5 fibroblasts and HeLa cells
with IL-1a resulted in activation of the JNK isoforms precipitated
by all three antibodies (Figure 1B). No significant activity was
precipitated from IL-1-treated cells by non-immune rabbit serum
or by the specific antibodies from unstimulated cells. Stimulation
by IL-1a resulted in strong activation of JNK1 in HeLa cells,
with less JNK2 and even less JNK3 detected. In contrast, JNK3
was the predominant JNK detected in IL-1a-stimulated fibro-
blasts.
Figure 4 Activation of MKK4 and MKK7 by IL-1 in rabbit liver
Immunoprecipitates were prepared from lysates of unstimulated (C) or IL-1-stimulated rabbit
liver by using antibodies against MKK4 and MKK7. Kinase assays were performed in vitro on
the precipitates with GST–JNK2 (K55R). Phosphorylated substrate was revealed by SDS/PAGE
and autoradiography. The result shown is typical of three experiments.
Identification of IL-1-activated JNK isoforms in rabbit liver
We previously showed by purification and peptide sequencing
that systemic administration of IL-1a caused a rapid activation
of short and long forms of JNK2 in rabbit liver [7]. We used the
various JNK antibodies to characterize further the IL-1a-
activated forms of JNK in rabbit liver. Liver homogenates were
prepared from IL-1a-injected animals and were chromato-
graphed on a MonoQ column. Aliquots of column fractions were
immunoprecipitated with each of the four antibodies. JNK
activity in the fractions (Figure 2A, top two panels) and in the
immunoprecipitates (Figure 2A, bottom four panels) was
measured. Two main peaks of JNK activity were eluted by
the gradient. Activity from the first peak was precipitated by the
antibody against JNK1, and from the second by the antiserum
against long JNK2. The antiserum against short JNK2
precipitated activity between the two peaks. The antiserum
against JNK3 precipitated no detectable activity. The fact that
there was no distinct peak of JNK activity corresponding to
short JNK2 suggested that it was a relatively minor component
compared with long JNK2 and JNK1.
Activated hepatic JNK1 is predominantly the p46 form
In-gel kinase assay of fractions from MonoQ chromatography of
IL-1a-stimulated rabbit liver (Figure 2B) revealed two main
peaks of Jun phosphorylation: a p46 JNK activity that was
eluted as an early, sharp peak (fractions 3 and 4; 30–60 mM
NaCl), and a p54 JNK activity that was eluted as a later,
broad peak (fractions 7–13; 90–195 mM NaCl). In addition, a
minor peak of p46 JNK was eluted between the two main peaks
(fractions 10 and 11; 90–120 mM NaCl) and a minor peak of p54
JNK activity was approximately co-eluted with the main p46
peak. The main peak of long JNK corresponds to the activity
precipitated by the anti-(long JNK2) antiserum, and the minor
peak of short JNK to that precipitated by the anti-(short JNK2)
antiserum; the in-gel assay thus confirmed that activated hepatic
JNK2 is primarily the long form. Both the early peaks detected
by the in-gel assay (the minor long peak and the main short peak)
were precipitated by the anti-JNK1 monoclonal antibody (Figure
2C). Thus the activated hepatic JNK1 (in contrast with JNK2)
is predominantly in the short form, with a small amount of the
long form (identifiable by in-gel kinase assay).
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Figure 5 IL-1 activates p38 MAPK and IjB degradation but not ERK in
rabbit liver
(A) Immunoprecipitates were prepared from extracts of livers from six animals (three control
and three injected with IL-1 as before) with the anti-(p38 MAPK) antiserum. Immunoprecipitated
p38 MAPK activity was measured on His6-MAPKAPK-2 substrate. See the Materials and
methods section for details. (B) Anti-ERK-2 immunoprecipitates were prepared from extracts of
liver and skeletal muscle from vehicle-injected or IL-1-injected rabbits ; ERK-2 activity was
measured against myelin basic protein substrate. The result shown is typical of three
experiments. (C) Liver extracts were prepared as before ; 1 mg of tissue protein was analysed
by SDS/PAGE, transferred to PVDF membrane and IjB was detected by blotting with anti-IjB
antibody at 1 : 1000 dilution. See the Materials and methods section for details. The result
shown is typical of three experiments.
IL-1a activates JNK1 and JNK2 but not JNK3 in other tissues
The anti-JNK antibodies were then used to examine whether IL-
1a caused a similar profile of JNK activation in other tissues.
Rabbits were injected intravenously with IL-1, left for 4 min and
killed as before. Tissues were rapidly removed and placed on ice
before the preparation of extracts at 4 °C. Immunoprecipitation
assays were performed with the various antibodies. Figure 3(A)
shows a representative experiment. IL-1a caused the activation
of long JNK2 and JNK1 in lung, spleen, kidney and skeletal
muscle as well as in liver. The mean levels of activation varied
from 30-fold in liver to 7-fold in skeletal muscle. No significant
JNK3 activity was detected in any tissue apart from brain. Little
activation of the JNK isoforms was detected in brain (1–2-fold in
several experiments) (Figures 3A and 3B).
IL-1a activates both MKK4 and MKK7 in rabbit liver
Two JNK activators are known: MKK4 and MKK7. It has been
reported that in some cell lines IL-1 activates MKK7 and not
MKK4, whereas both JNK kinases are activated in response to
stressful stimuli [19–21]. We measured the activity of both of
these kinases by immunoprecipitating them from liver extracts
and assaying their ability to phosphorylate a kinase-dead JNK
substrate. Figure 4 shows a representative experiment in which
IL-1a caused approx. 6-fold activation of both enzymes.
IL-1a activates p38 MAPK and IjB degradation, but not ERK, in
rabbit liver
We next investigated the activation in liver of other signalling
pathways known to be stimulated by IL-1 in cultured cells. The
activity of p38 MAPK was measured by immunoprecipitation
assay of extracts prepared as before. Three pairs of livers (control
and IL-1) were used. IL-1a caused a 2–3-fold activation (Figure
5A). Significant variation in the levels of p38 activity between
extracts from the three unstimulated livers was observed.
IL-1a did not cause an activation of ERK-2 in liver or skeletal
muscle, as judged by an immunoprecipitation assay on myelin
basic protein (Figure 5B). This contrasts with a strong activation
of ERK by IL-1 previously observed in many cell lines [5,22].
Lastly we checked whether IL-1a caused the degradation of
IjB. Tissue extracts were prepared 6 and 20 min after the
injection of IL-1a and then Western blotted. The hepatic IjB had
been degraded by 6 min, which was consistent with expected
activation of the NF-jB pathway (Figure 5C).
DISCUSSION
The physiological reasons for the existence of three JNK genes
and at least ten potential isoforms remain unclear. Charac-
terization of the various JNK antibodies described here showed
that they were specific for the form used as antigen. For this
reason we used them to characterize further the JNK forms
activated by IL-1a in io in the liver, which is an important
target tissue. Most of the JNK activated by IL-1a comprised the
short form of JNK1 and the long form of JNK2. Long JNK1
and short JNK2 seemed to be minor components. No JNK3 was
detected, which was surprising because the antibody against
short JNK3 strongly precipitates IL-1a activated JNK from a
variety of cultured cells, including fibroblasts and HeLa cells
(Figure 1B), and vascular endothelial cells [22]. A relatively large
amount of JNK3 activity was found in the brain but there was
little regulation by IL-1a compared with that seen in other
tissues. This pattern was consistent with the reported distribution
of JNK3 mRNA in mouse tissues, in which significant expression
was restricted to brain and testis [17]. This suggests that the
relative activities of JNK isoforms detected in tissues is likely to
reflect the relative expression of the three JNK genes; certainly
we have found no evidence for the differential activation of
isoforms by different stimuli in cultured cells (W. Davis and
J. Saklatvala, unpublished work).
The activation of hepatic JNKs after injection of IL-1a is
presumably by MKK4 as well as MKK7, because both these
upstream kinases were activated. This finding contrasts with
some reports in cell lines in which IL-1 has been found to activate
only MKK4, although both JNK kinases were reported to be
activated by stressful stimuli [19–21]. We have also found the
regulation of MKK4 (as well as MKK7) by IL-1a, with the assay
described, in many cell lines including pig aortic endothelial cells
and KB cells (W. Davis and J. Saklatvala, unpublished work).
We previously purified an IL-1-induced activator, identified as
MKK7, from rabbit liver [16]. In that work JNK activation was
measured by its ability to phosphorylate c-Jun; MKK4 was not
detected. It is interesting to consider the finding of strong
activation of both kinases in io in the light of the findings of
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Lawler et al. [21]. They showed that, in itro, MKK4 exhibited a
strong preference for the tyrosine residue in the JNK
phosphorylation motif (TPY) and did not phosphorylate
the threonine residue. MKK7, in contrast, phosphorylated the
threonine residue preferentially but was also able to
phosphorylate the tyrosine residue, although to a much smaller
extent. To be active, MAPKs need both hydroxyamino acids to
be phosphorylated. Consequently MKK4 acting alone might not
be a significant activator but might synergize strongly with
MKK7. We found that both MKKs were activated in io by IL-
1a approx. 6-fold: this would result in a synergistic activation,
which is consistent with the level of activation that we observe
(approx. 30-fold).
Maximal JNK activation therefore might require two acti-
vators. This contrasts with ERK and p38 MAPKs, whose MKKs
show a more equal preference for the tyrosine and threonine
residues of their respective activation motifs. The need for two
activators raises the possibility that they could be regulated
separately and might be activated by different upstream kinases.
Generally, MKK4 has been thought to be activated by MEKK1
[23,24], whereas MKK7 might be activated by mixed-lineage
kinase 3 (‘MLK3’) because of the association of MKK7 and
MLK3 with the JNK-interacting protein (‘JIP’) [25].
Besides investigating the JNK pathway components activated
by IL-1a in a physiological system in io, we also examined the
other pathways known to be activated by IL-1 in cell culture.
Both p38 MAPK and IjB degradation were also stimulated in
liver, although a lower activation of p38 than that caused by IL-
1a in many cell lines [26,27] was observed. This suggests that the
p38 pathway in io is less responsive to IL-1a than is the JNK
pathway, in which comparable activation to that observed in cell
lines is elicited by injection of the cytokine. In our previous study
we were unable to show convincing activation of p38 [16]. This
might have been because there was variation in basal activity
between different liver samples. In these experiments we used
three separate pairs of animals. However, we were still unable to
find evidence of activation of ERK by IL-1, although this is
widely found in cells in culture. We have also been unable to
detect activation of TIPK in tissues of IL-1-injected rabbits (A.
Finch and J. Saklatvala, unpublished work). It might be that
differentiated non-dividing cells respond to IL-1 in a limited
manner in io, whereas dividing ‘repair ’ cells such as fibroblasts
undergo a wider range of changes in gene expression in response
to the cytokine. Many cultured cells might resemble this ‘ repair ’
phenotype more closely than that of differentiated, resting tissue,
and might therefore respond to IL-1 by activating more in-
tracellular signalling pathways. The expression of significant
levels of JNK3 in these cells, as well as the responsiveness to IL-
1 of the ERK and TIPK pathways, might be a reflection of this
difference.
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